Valo Health to Present at the BMO BioPharma Spotlight Series

CEO David Berry to Highlight Valo as Part of Technology-Enabled Drug Discovery

BOSTON, MA (April 6, 2021) — Valo Health LLC (Valo), the tech­nol­o­gy com­pa­ny that is using human-cen­tric data, machine learn­ing com­pu­ta­tion and life sci­ence exper­tise to trans­form and accel­er­ate the drug dis­cov­ery and devel­op­ment process, today announced that David Berry, Ph.D., founder and Chief Exec­u­tive Offi­cer of Valo will present at the BMO Bio­Phar­ma Spot­light Series on Fri­day, April 16, 2021 at 11:55 ET. Berry’s pre­sen­ta­tion will be part of BMO’s series enti­tled Com­pa­ny Spot­lights: Tech­nol­o­gy-Enabled Drug Dis­cov­ery.” Dur­ing the pre­sen­ta­tion Berry will pro­vide an overview of Valo, its Opal Com­pu­ta­tion­al Plat­form™ and a selec­tion of its ther­a­peu­tic programs. 

The pre­sen­ta­tion and a replay of the web­cast will be avail­able in the News & Investors sec­tion of the Company’s web­site at https://​www​.val​o​health​.com/inv…

About Valo

Valo Health, LLC (Valo) is a tech­nol­o­gy com­pa­ny that is using human-cen­tric data and machine learn­ing com­pu­ta­tion to trans­form the drug dis­cov­ery and devel­op­ment process. As a dig­i­tal­ly native com­pa­ny, Valo is the first to ful­ly inte­grate human-cen­tric data across the entire drug devel­op­ment life­cy­cle into a sin­gle uni­fied archi­tec­ture, there­by accel­er­at­ing the dis­cov­ery and devel­op­ment of life-chang­ing drugs while simul­ta­ne­ous­ly reduc­ing the cost, time, and fail­ure rate. The com­pa­ny’s Opal Com­pu­ta­tion­al Plat­form™, a ful­ly inte­grat­ed, com­pu­ta­tion­al, end-to-end drug devel­op­ment plat­form, offers a unique approach to ther­a­peu­tic devel­op­ment that enables Valo to advance a robust pipeline of can­di­dates across car­dio­vas­cu­lar dis­ease, oncol­o­gy, and neu­rode­gen­er­a­tion. Found­ed by Flag­ship Pio­neer­ing and head­quar­tered in Boston, MA, Valo has offices in Lex­ing­ton, MA, San Fran­cis­co, CA, Prince­ton, NJ, and in Bran­ford, CT. To learn more, vis­it www​.val​o​health​.com.


Investors: Graeme Bell, Chief Finan­cial Officer


Media: Jen­nifer Han­ley, VP Cor­po­rate Communications